Palonosetron, a 5-HT3 receptor antagonist, inhibited gastric cancer progression by suppressing cell proliferation, migration, and colony formation via induction of G1 cell cycle arrest and promoting autophagy through activation of the GSK3β. Here, GSK3B is linked to gastric cancer.